ADx NeuroSciences and Alamar Biosciences announce partnership to provide customized blood-based biomarker assay solutions to accelerate biopharma clinical development

We’re proud to announce our collaboration with Alamar Biosciences, Inc.!

“By adding the NULISA platform with its remarkable sensitivity to our range of possible platforms, it enforces our capabilities to support our pharma network in their search for tailor-made biomarkers” – Koen Dewaele (CEO, ADx)

To read the full story behind this partnership, check out the press release!